Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy
Abstract Glioblastoma (GBM) is characterized by rapid growth, high molecular heterogeneity, and invasiveness. Specific aggressive factors are represented by MGMT promoter methylation, and IDH mutation status. Current standard-of-care for GBM includes surgical resection, followed by radiotherapy plus...
Saved in:
| Main Authors: | Susan Costantini, Elena Di Gennaro, Giulia Fanelli, Palmina Bagnara, Chiara Argenziano, Carmen Maccanico, Marco G. Paggi, Alfredo Budillon, Claudia Abbruzzese |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03497-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolomic characterisation of the glioblastoma invasive margin reveals a region-specific signature
by: James Wood, et al.
Published: (2025-01-01) -
Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy
by: Susan Costantini, et al.
Published: (2025-04-01) -
Ferroptosis determinants - potential therapeutic targets glioblastoma stem cells
by: V. E. Shevchenko, et al.
Published: (2022-10-01) -
Identification of predictive markers in the cerebrospinal fluid of patients with glioblastoma
by: N. E. Arnotskaya, et al.
Published: (2023-07-01) -
RNA-seq data analysis uncovers a link between systemic lupus erythematosus and glioblastoma
by: Nahshon A. Puente, et al.
Published: (2025-06-01)